Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis

Thrombosis Research

Volumn 130, Issue 1, 2012, Pages 38-44

  Liang, Ruijuan ^a   Wang, Chunling ^a   Zhao, Hong ^a   Huang, Jie ^a   Hu, Dayi ^a   Sun, Yihong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

CYP4F2; Genetics; Meta analysis; Polymorphisms; Warfarin

Indexed keywords

CYTOCHROME; CYTOCHROME P450 4F2; UNCLASSIFIED DRUG; WARFARIN;

AFRICAN AMERICAN; ANTICOAGULANT THERAPY; ASIAN; BLEEDING; CAUCASIAN; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 84861150804     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.11.043     Document Type: Article

References (39)

1. H. Takahashi, G.R. Wilkinson, E.A. Nutescu, T. Morita, M.D. Titchie, and M.G. Scordo Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogenet Genomics 16 2006 101 110
2. E.A. Sconce, T.I. Khan, H.A. Wynne, P. Avery, L. Monkhouse, and B.P. King The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2005 2329 2333
3. H. Schelleman, J. Chen, Z. Chen, J. Christie, C.W. Newcomb, and C.M. Brensinger Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans Clin Pharmacol Ther 84 2008 332 339
4. M.T. Lee, C.H. Chen, C.H. Chou, L.S. Lu, H.P. Chuang, and Y.T. Chen Genetic determinants of warfarin dosing in the Han-Chinese population Pharmacogenomics 10 2009 1905 1913
5. L.H. Cavallari, T.Y. Langaee, K.M. Momary, N.L. Shapiro, E.A. Nutescu, and W.A. Coty Genetic and clinical predictors of warfarin dose requirements in African Americans Clin Pharmacol Ther 87 2010 459 464
6. T.E. Klein, R.B. Altman, N. Eriksson, B.F. Gage, S.E. Kimmel, and M.T. Lee Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
7. F. Takeuchi, R. McGinnis, S. Bourgeois, C. Barnes, N. Eriksson, and N. Soranzo A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLoS Genet 5 2009 e1000433
8. P.S. Wells, H. Majeed, S. Kassem, N. Langlois, B. Gin, and J. Clermont A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism Thromb Res 125 2010 e259 e264
9. M.D. Caldwell, T. Awad, J.A. Johnson, B.F. Gage, M. Falkowski, and P. Gardina CYP4F2 genetic variant alters required warfarin dose Blood 111 2008 4106 4112
10. P.C. Cha, T. Mushiroda, A. Takahashi, M. Kubo, S. Minami, and N. Kamatani Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese Hum Mol Genet 19 2010 4735 4744
11. P.K. Powell, I. Wolf, R. Jin, and J.M. Lasker Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11 J Pharmacol Exp Ther 285 1998 1327 1336
12. T.J. Sontag, and R.S. Parker Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status J Biol Chem 277 2002 25290 25296
13. M.G. McDonald, M.J. Rieder, M. Nakano, C.K. Hsia, and A.E. Rettie CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant Mol Pharmacol 75 2009 1337 1346
14. P.T. Julian, Higgins, and Green Sally The Cochrane Handbook: v5.1.0 2011 part 2:8.5.
15. J. Little, L. Bradley, M.S. Bray, M. Clyne, J. Dorman, and D.L. Ellsworth Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations Am J Epidemiol 156 2002 300 310
16. P. Juni, A. Witschi, R. Bloch, and M. Egger The hazards of scoring the quality of clinical trials for meta-analysis JAMA 282 1999 1054 1060
17. J.D. Lindh, L. Holm, M.L. Andersson, and A. Pane Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis Eur J Clin Pharmacol 65 2009 365 375
18. L. Yang, W. Ge, F. Yu, and H. Zhu Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis Thromb Res 125 2010 e159 e166
19. P. Borgiani, C. Ciccacci, V. Forte, E. Sirianni, L. Novelli, and P. Bramanti CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population Pharmacogenomics 10 2009 261 266
20. J.F. Carlquist, B.D. Horne, C. Mower, J. Park, J. Huntinghouse, and J.T. McKinney An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction J Thromb Thrombolysis 30 2010 358 364
21. T. Harada, N. Ariyoshi, H. Shimura, Y. Sato, I. Yokoyama, and K. Takahashi Application of Akaike information criterion to evaluate warfarin dosing algorithm Thromb Res 126 2010 183 190
22. H.J. Cen, W.T. Zeng, X.Y. Leng, M. Huang, X. Chen, and J.L. Li CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement Br J Clin Pharmacol 70 2010 234 240
23. J.E. Zhang, A.L. Jorgensen, A. Alfirevic, P.R. Williamson, C.H. Toh, and B.K. Park Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy Pharmacogenet Genomics 19 2009 781 789
24. H. Sagreiya, C. Berube, A. Wen, R. Ramakrishnan, A. Mir, and A. Hamilton Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9 Pharmacogenet Genomics 20 2010 407 413
25. E. Pautas, C. Moreau, I. Gouin-Thibault, J.L. Golmard, I. Mahé, and C. Legendre Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients Clin Pharmacol Ther 87 2010 57 64
26. O. Singh, E. Sandanaraj, K. Subramanian, L.H. Lee, and B. Chowbay The influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients Drug Metab Pharmacokinet 26 2011 130 136
27. C.F. Zambon, V. Pengo, R. Padrini, D. Basso, S. Schiavon, and P. Fogar VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study Pharmacogenomics 12 2011 15 25
28. M.K. Kringen, K.B. Haug, R.M. Grimholt, C. Stormo, S. Narum, and M.S. Opdal Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction J Biomed Biotechnol 2011 2011 739751
29. Z.H.A.N.G. Hai-yan, L.U.O. Wan-wei, M.A. Shou-mei, and X.U. Lian-hong Association of CYP4F2 Gene Polymorphism with Warfarin Dose Pharm Clin Res 18 4 2010 338 340
30. J.F. Carlquist, B.D. Horne, J.B. Muhlestein, D.L. Lappé, B.M. Whiting, and M.J. Kolek Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study J Thromb Thrombolysis 22 2006 191 197
31. P. Borgiani, C. Ciccacci, V. Forte, S. Romano, G. Federici, and G. Novelli Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians Pharmacogenomics 8 2007 1545 1550
32. D.L. Veenstra, J.H. You, M.J. Rieder, F.M. Farin, H.W. Wilker, and D.K. Blough Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenet Genomics 15 2005 687 691
33. M. Wadelius, L.Y. Chen, K. Downes, J. Ghori, S. Hunt, and N. Eriksson Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 2005 262 270
34. C. Geisen, M. Watzka, K. Sittingger, M. Steffens, L. Daugela, and E. Seifried VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb Haemost 94 2005 773 779
35. H.Y. Yuan, J.J. Chen, M.T. Lee, J.C. Wung, Y.F. Chen, and M.J. Charng A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum Mol Genet 14 2005 1745 1751
36. Y. Zhu, M. Shennan, K.K. Reynolds, N.A. Johnson, M.R. Herrnberger, and R. Valdes Jr. Estimation of warfarin maintenance dose based on VKORC1 (- 1639 G>A) and CYP2C9 genotypes Clin Chem 53 2007 1199 1205
37. B.F. Gage Pharmacogenetics-based coumarin therapy Hematology Am Soc Hematol Educ Program 2006 467 473
38. J.L. Anderson, B.D. Horne, S.M. Stevens, A.S. Grove, S. Barton, and Z.P. Nicholas Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 22 2007 2563 2570
39. M.D. Caldwell, R.L. Berg, K.Q. Zhang, I. Glurich, J.R. Schmelzer, and S.H. Yale Evaluation of genetic factors for warfarin dose prediction Clin Med Res 5 2007 8 16